May transiently slow ventricular rate or reveal atrial activity
Avoid if carotid bruit or known stenosis
Technique
Firm steady pressure 5 to 10 seconds right then left
Monitor rhythm continuously during maneuver
Targeted exam
Thyroid exam
Goiter palpation
Hyperthyroidism as AT precipitant
Exophthalmos or tremor
Signs of thyrotoxicosis
Warm moist skin
Fine tremor
Pulmonary exam
Wheezing or crackles
COPD or pulmonary disease in MAT
Heart failure pulmonary edema
Respiratory rate and work of breathing
Pulmonary decompensation indicator
AT consequence vs cause
PITFALLS
Diagnostic pitfalls
Sinus tachycardia misidentified as AT
P-wave morphology identical to baseline sinus in inappropriate sinus tachycardia
Abrupt onset and offset on monitoring distinguishes AT
MAT misidentified as AF
Both irregularly irregular
MAT has discrete P waves with three or more morphologies
Wide complex AT with aberrant conduction
Do not assume SVT with aberrancy is safe
Treat as VT if uncertain
Differential Diagnosis
Life-threatening mimics
Ventricular tachycardia
Wide complex tachycardia
ICD-10 I47.2
AV dissociation on ECG
Differentiating features
Fusion beats and capture beats
Brugada criteria application
Pre-excited tachycardia with WPW
AF with pre-excitation
ICD-10 I45.6
Irregular wide complex tachycardia at very rapid rates
Risk of sudden cardiac death
Avoid AV nodal blocking agents
Cardioversion preferred
Atrial flutter with 2:1 conduction
Sawtooth pattern
ICD-10 I48.3 or I48.4
Atrial rate typically 300 bpm
Differentiating feature
No isoelectric baseline between flutter waves
Adenosine reveals flutter waves
SVT mimics
AVNRT
Most common SVT
ICD-10 I47.1
Short RP tachycardia
ECG features
Pseudo R prime in V1
Pseudo S in inferior leads
AVRT orthodromic
Short RP tachycardia
Delta wave in sinus rhythm
ICD-10 I47.1 with WPW context
Differentiating feature
Pre-excitation visible during sinus rhythm
Sinus tachycardia and inappropriate sinus tachycardia
Gradual onset and offset
ICD-10 R00.0 or I49.8
P-wave morphology identical to baseline
Inappropriate sinus tachycardia
Mean 24-hour rate > 90 bpm
Diagnosis of exclusion
AT variants and coding
Focal atrial tachycardia
ICD-10 I47.1
SNOMED CT focal atrial tachycardia
Accounts for 10 to 17% of SVTs referred for ablation
Multifocal atrial tachycardia
ICD-10 I47.1
Associated with pulmonary disease and critical illness
Treatment targets underlying condition
Atrial fibrillation
ICD-10 I48.0 to I48.19
Irregularly irregular no discrete P waves
Differentiate from MAT
Laboratory Tests
Core metabolic labs
Electrolytes
Potassium
Hypokalemia lowers arrhythmia threshold
Target replete to > 4.0 mmol/l before antiarrhythmics
Magnesium
Hypomagnesemia key trigger especially in MAT
IV magnesium even if levels normal in MAT
Calcium
Hypercalcemia arrhythmia risk
Hypocalcemia potentiates QT prolongation
Renal function
Creatinine and eGFR
Digoxin dosing and toxicity threshold adjustment
Antiarrhythmic dosing adjustment
BUN
Dehydration context
Prerenal state identification
Endocrine and toxicology
Thyroid function
TSH
Rule out hyperthyroidism as precipitant
Obtain in new-onset AT without clear cause
Free T4 if TSH suppressed
Thyrotoxicosis severity
Guides urgency of endocrine consultation
Drug levels and toxicology
Digoxin level
Toxicity at levels > 2 ng/mL
AT with AV block pattern classic for digoxin toxicity
Theophylline level
Toxicity at levels > 20 mcg/mL
Theophylline-induced AT mechanism
Urine drug screen
Cocaine and amphetamine detection
Stimulant-induced AT
Cardiac biomarkers and function
Troponin
High sensitivity troponin
Demand ischemia from sustained rapid rate
ACS in differential if chest pain
Serial measurement if initial elevated
Delta troponin at 1 to 3 hours
Clinical correlation required
BNP or NT-proBNP
Heart failure decompensation assessment
Tachycardia-mediated cardiomyopathy concern
Baseline for comparison
Interpretation in tachycardia context
Rate-related elevation possible
Trend more useful than single value
Complete blood count
Anemia as precipitant
Compensatory tachycardia mechanism
Hemoglobin threshold for clinical significance
White cell count
Infection as MAT trigger
Sepsis evaluation context
Diagnostic Tests
Scoring Systems
SVT risk stratification
No validated emergency tachycardia score specific to AT
Clinical gestalt and hemodynamic assessment primary
Mechanism determination guides therapy
CHA2DS2-VASc not applicable to focal AT
Applies to AF thromboembolic risk
Do not conflate with AT management
Tachycardia-mediated cardiomyopathy risk
Incessant AT duration as risk stratifier
Weeks to months of rapid rate required to cause cardiomyopathy
EF typically normalizes after successful treatment
Echo-based EF at presentation
EF < 40% with incessant AT suggests tachycardia-mediated cardiomyopathy
Urgent rate control or ablation indicated
MRI
Cardiac MRI role in AT
Limited acute utility
Not a first-line emergency diagnostic
Rate and motion artifact limit image quality during tachycardia
Pre-ablation structural assessment
Scar characterization in structural heart disease
Congenital anatomy in complex AT
Contraindications
Hemodynamic instability
Non-MRI compatible devices or implants
CT
CT indications in AT evaluation
Pulmonary embolism exclusion
AT in differential of new PE with tachycardia
CT pulmonary angiography if clinical concern
Pulmonary parenchymal evaluation in MAT
COPD or pulmonary disease extent
Infection or consolidation as MAT trigger
Coronary CT angiography
Selected cases to exclude ischemic substrate
Not routine in AT evaluation
Limitations
Radiation exposure considerations
CT not required if echo and ECG diagnostic
Reserve for specific clinical questions
Ultrasound
Transthoracic echocardiography
Structural heart disease assessment
Recommended for all new-onset AT
LV function and wall motion
Tachycardia-mediated cardiomyopathy detection
EF measurement at presentation
Repeat echo after rate control to reassess
Valvular disease evaluation
Stenosis or regurgitation as AT substrate
Severity grading
Point of care echocardiography
Hemodynamic assessment in unstable AT
Gross LV function
Pericardial effusion exclusion
Volume status adjunct
IVC collapsibility
Integration with clinical exam
Transesophageal echocardiography
Pre-cardioversion thrombus exclusion if duration uncertain and AT with structural disease
Left atrial appendage thrombus
More relevant in AF but consider in prolonged AT with structural disease
Atrial anatomy in pre-ablation planning
Pulmonary vein anatomy
Complex structural assessment
Disposition
Admission criteria
Indications for hospital admission
Hemodynamic instability
SBP < 90 mmHg at any point
Cardioversion required in ED
Refractory tachycardia
Failure to terminate or rate control with ED management
IV antiarrhythmic initiation required
Suspected tachycardia-mediated cardiomyopathy
New low EF with incessant AT
Heart failure symptoms
Digoxin toxicity
AT with AV block pattern
Telemetry and digoxin-specific Fab consideration
MAT with pulmonary decompensation
Acute COPD exacerbation or pneumonia trigger
Oxygen requirement
ICU indications
Shock requiring vasopressors
Tachyarrhythmia contributing to cardiogenic shock
Hemodynamic monitoring required
Wide complex tachycardia requiring urgent EP consultation
Uncertain mechanism
Failed cardioversion
Discharge criteria
Safe discharge requirements
Conversion to sinus rhythm
Documented on 12-lead ECG
Hemodynamically stable
No structural heart disease or known cardiomyopathy
Normal or near-normal echo
Brief well-tolerated episodes
Clear precipitant identified and addressed
Stimulant cessation counseling
Electrolyte correction completed
Reliable follow-up arranged
Cardiology referral within 1 to 2 weeks
Return precautions provided
Specialist consultation before discharge
Pre-excitation or delta wave on ECG
Cardiology evaluation required
WPW-associated sudden death risk
Syncope with AT
Mandatory cardiology referral
Driving restriction counseling
Uncertain diagnosis
Wide complex tachycardia mechanism unclear
Recurrent episodes without clear substrate
Treatment
Acute stabilization
Vagal maneuvers first line
Modified Valsalva maneuver
Strain for 15 seconds then supine with passive leg raise
Success rate approximately 50% with leg raise modification
Carotid sinus massage
Right side first
Avoid with carotid bruit or stenosis
Mechanism
Increases vagal tone transiently
May terminate reentrant AT or reveal atrial activity in automatic AT
Pharmacologic acute treatment
Adenosine
Adenosine 6 mg rapid IV push
Follow immediately with 20 mL normal saline flush
If no response after 1 to 2 minutes give 12 mg rapid IV push
Second dose
12 mg IV rapid push
May repeat 12 mg once more if needed
Diagnostic and therapeutic role
Terminates triggered or microreentrant AT
Transiently suppresses automatic AT revealing underlying atrial activity
Reveals atrial flutter waves
Contraindications
Severe asthma or bronchospasm
Pre-excitation with WPW
Second or third degree AV block
IV diltiazem for rate control or termination
Diltiazem 20 mg IV over 2 minutes
If no response after 15 minutes give 25 mg IV
Maintenance infusion 5 to 15 mg/hour if needed
Contraindications
HFrEF with EF < 40%
Hemodynamic instability
Pre-excitation with WPW
Evidence base
Class IIa recommendation 2015 ACC/AHA/HRS SVT guideline
IV verapamil
Verapamil 5 mg IV over 2 minutes
May repeat 5 to 10 mg every 15 to 30 minutes
Maximum 30 mg total
Contraindications
HFrEF
Wide complex tachycardia
Hemodynamic instability
Alternative to diltiazem
Similar efficacy for focal AT
Not preferred over diltiazem in emergency setting
IV beta-blockers
Metoprolol tartrate 5 mg IV over 2 minutes
May repeat every 5 minutes up to 3 doses
Total maximum 15 mg IV
Esmolol IV loading
500 mcg/kg bolus over 1 minute
Maintenance 50 mcg/kg/minute
Titrate 25 to 50 mcg/kg/minute every 5 to 15 minutes
Maximum 300 mcg/kg/minute
Preferred when structural disease relative contraindication to CCB
Caution in severe bronchospastic disease
Class IIa recommendation 2015 ACC/AHA/HRS SVT guideline
IV amiodarone
Amiodarone 150 mg IV over 10 minutes
Followed by 1 mg/minute infusion for 6 hours
Then 0.5 mg/minute for 18 hours
Preferred when reduced EF or heart failure
Does not worsen LV function significantly
Class IIa recommendation for AT with reduced EF
Caution
Phlebitis with peripheral infusion
QT prolongation monitoring
Electrical cardioversion
Synchronized cardioversion
50 to 100 J biphasic initial energy
Escalate if unsuccessful
Sedation with procedural agent before cardioversion
Indications
Hemodynamic instability refractory to medications
Patient preference for rapid termination
Limitations for automatic AT
Cardioversion unlikely to terminate automatic AT mechanism
Rate control agents preferred for automatic AT
Evidence
Class I recommendation for unstable SVT AHA 2025 ACLS guideline
Multifocal AT specific treatment
Treat underlying condition first
COPD exacerbation management
Bronchodilators and corticosteroids
Oxygen with target 88 to 92% in COPD
Correct metabolic derangements
Hypoxia correction priority
Acid-base normalization
IV magnesium
Magnesium sulfate 2 g IV over 10 to 20 minutes
Even if magnesium level is normal
Repeat 2 g if no response and levels permit
Mechanism
Stabilizes automaticity in multiple atrial foci
Class IIb recommendation for MAT
Rate control in MAT
Verapamil or diltiazem preferred in pulmonary disease
Diltiazem 20 mg IV as initial dose
Avoid non-selective beta-blockers in bronchospastic disease
Metoprolol after respiratory stabilization
Use with caution in active bronchospasm
5 mg IV if respiratory status allows
Cardioversion not effective for MAT
Not recommended for MAT
Class III harm recommendation
Long-term oral pharmacotherapy
First-line oral agents
Beta-blockers
Metoprolol succinate 25 to 100 mg PO daily extended release
Atenolol 25 to 100 mg PO daily as alternative
Diltiazem extended release
120 to 360 mg PO daily
Rate and rhythm control properties
Verapamil extended release
120 to 480 mg PO daily divided
Class IIa recommendation for symptomatic AT
Second-line antiarrhythmic agents
Flecainide
50 to 150 mg PO twice daily
Contraindicated in structural or ischemic heart disease
Pill-in-the-pocket option for infrequent episodes
Propafenone
150 to 300 mg PO three times daily
Contraindicated in structural or ischemic heart disease
Beta-blocking properties limit in bronchospastic disease
Third-line specialist-supervised agents
Sotalol
80 to 160 mg PO twice daily
QT monitoring required
Renal dose adjustment necessary
Amiodarone
200 mg PO daily maintenance after loading
Reserve for refractory cases or reduced EF
Long-term organ toxicity monitoring required
Dofetilide
Specialist initiation with telemetry required
QT-dependent dosing protocol
Catheter ablation
First-line for recurrent symptomatic focal AT
Acute success rate > 90 to 95%
Recurrence rate < 5%
Risk of inadvertent AV block < 1%
Higher risk for septal AT near AV node
Patient counseling required pre-procedure
Class I recommendation 2015 ACC/AHA/HRS SVT guideline
Preferred over long-term antiarrhythmic therapy
Cardiology or EP referral for ablation candidacy
Special Populations
Pregnancy
Pregnancy-specific considerations
Increased SVT susceptibility
Elevated catecholamines and blood volume
Hormonal effects on ion channels
Fetal heart rate monitoring
Maternal tachycardia affects fetal status
Obstetrics consultation in second and third trimester
Acute management in pregnancy
Vagal maneuvers first
Safe in all trimesters
Modified Valsalva preferred
Adenosine safe in pregnancy
Short half-life limits fetal exposure
Class IIa recommendation during pregnancy
Standard doses 6 mg then 12 mg IV
Metoprolol acceptable for rate control
Category C but widely used in pregnancy
Monitor for fetal bradycardia and IUGR
Verapamil use with caution
May cause fetal bradycardia
Avoid in first trimester if possible
Agents to avoid in pregnancy
Amiodarone
Fetal thyroid dysfunction and IUGR risk
Reserve for life-threatening refractory AT only
Flecainide and propafenone
Limited safety data in pregnancy
Specialist guidance required
Sotalol and dofetilide
Avoid due to fetal risk
Category B/D designations
Geriatric
Physiologic changes in older adults
Reduced sinoatrial and AV nodal function
Increased sensitivity to AV nodal blocking agents
Start at lower doses of diltiazem or beta-blockers
Reduced renal clearance
Digoxin dosing careful adjustment
Sotalol renal dosing required
Medication safety considerations
Verapamil caution
Constipation and hypotension risk higher
Drug interaction risk with polypharmacy
QT prolongation risk elevated
Avoid multiple QT-prolonging agents
Baseline QT measurement required
Fall risk with antiarrhythmics
Dizziness and hypotension more common
Orthostatic blood pressure assessment
Multifocal AT in older adults
Higher prevalence of pulmonary disease substrate
COPD and heart failure common comorbidities
Treat underlying disease as primary intervention
Theophylline use in older COPD patients
Drug level monitoring essential
Narrow therapeutic window
Pediatrics
Pediatric AT features
Focal AT accounts for up to 15% of SVT in children
Often incessant in infants leading to cardiomyopathy
Higher rate of spontaneous resolution in infants vs adults
Presentation differences
Infants present with irritability poor feeding and tachypnea
Older children report palpitations
Acute management in pediatrics
Vagal maneuvers age-appropriate
Ice to face for infants
Valsalva for older children
Adenosine weight-based dosing
0.1 mg/kg IV rapid push initial dose
Maximum 6 mg initial dose
Second dose 0.2 mg/kg up to 12 mg maximum
Synchronized cardioversion if hemodynamically unstable
0.5 to 1 J/kg initial
Escalate to 2 J/kg if needed
Long-term pediatric management
Catheter ablation effective in children > 15 to 20 kg
Success rates > 90% in pediatric EP programs
Preferred over long-term antiarrhythmics in older children
Propranolol first-line oral agent in infants
1 to 4 mg/kg/day divided three to four times daily
Monitor for hypoglycemia in neonates
Digoxin in infants with reduced EF
8 to 10 mcg/kg/day maintenance divided twice daily
Serum level monitoring required
Background
Epidemiology
Prevalence and incidence
AT accounts for 10 to 17% of SVTs referred for ablation
2015 ACC/AHA/HRS SVT Guideline estimate
True prevalence higher as many not referred
Age distribution
Focal AT occurs across all ages including young adults
Prevalence increases with age
Sex distribution
Slight female predominance for SVT overall
No strong sex predominance specifically for AT
Disease burden
Tachycardia-mediated cardiomyopathy in up to 10% of incessant cases
EF recovers after successful treatment in most patients
Underdiagnosed as a cause of cardiomyopathy
MAT mortality related to underlying disease severity
High in-hospital mortality driven by COPD or sepsis substrate
MAT itself not independently lethal
High premature atrial complex burden as risk factor
PAC burden > 500 per 24 hours increases AF progression risk
Shared atrial substrate with AT
Pathophysiology
Mechanisms of focal AT
Enhanced automaticity
Abnormal phase 4 depolarization in ectopic atrial focus
Warm-up and cool-down phenomenon over 5 to 10 seconds
Triggered activity
Delayed or early afterdepolarizations
Common with catecholamine excess or digoxin toxicity
Microreentry
Small reentrant circuit within atrial tissue
Abrupt onset and termination
Terminates with adenosine
Common anatomic origins of focal AT
Crista terminalis right atrium
Most common right-sided location
Pulmonary veins and left atrium
Especially perimitral region
Overlap with AF substrate
Coronary sinus region
Posteroseptal location
Para-Hisian region
Ablation risk of inadvertent AV block
Multifocal AT pathophysiology
Multiple ectopic atrial foci
Triggered by metabolic derangement or catecholamine excess
Hypoxia and acidosis reduce atrial action potential stability
Hypomagnesemia
Magnesium deficiency destabilizes automaticity in multiple foci
IV magnesium effective even with normal serum levels
Therapeutic Considerations
Rate control vs rhythm control decision
Rhythm control preferred for focal AT
Catheter ablation as definitive therapy
Antiarrhythmics as temporizing or alternative
Rate control acceptable for MAT
Rhythm control not achievable while multiple foci active
Underlying disease treatment primary goal
Catheter ablation considerations
P-wave morphology guides ablation target
Positive P wave in V1 with negative I and aVL suggests left atrial origin
Negative P in inferior leads suggests low right atrial or coronary sinus origin
Electrophysiology study required before ablation
Gold standard for mechanism determination
Mapping of earliest atrial activation
Success and recurrence rates
Acute success > 90 to 95%
Recurrence rate < 5% with successful ablation
Antiarrhythmic selection principles
Structural heart disease limits drug choice
Flecainide and propafenone contraindicated with structural or ischemic disease
Amiodarone or sotalol if antiarrhythmic required with structural disease
QT monitoring mandatory with sotalol and dofetilide
Baseline QTc measurement required
Discontinue if QTc > 500 ms
Adenosine challenge as diagnostic tool
AT with AV block visible on adenosine = automatic AT
AT termination with adenosine = triggered or microreentrant AT
Patient Discharge Instructions
copy discharge instructions
Atrial tachycardia home care
Take all medications exactly as prescribed
Do not skip doses of rate control or antiarrhythmic medications
Do not stop without speaking to your doctor
Avoid known triggers
Caffeine including coffee tea energy drinks and sodas
Alcohol
Stimulant drugs or supplements
Lifestyle measures
Stay well hydrated
Regular sleep schedule
Moderate regular exercise as tolerated
Vagal maneuver self-treatment
Modified Valsalva technique
Blow hard into a syringe or closed lips for 15 seconds
Immediately lie flat and have someone raise your legs for 15 seconds
Can terminate many episodes of palpitations
When to use
Early in an episode before calling for help
Only if not lightheaded or unwell
Return to ER immediately for
Fainting or near-fainting
Loss of consciousness during palpitations
Feeling you are about to pass out
Chest pain during palpitations
Pressure squeezing or tightness in chest
Palpitations lasting more than 15 to 20 minutes
Not responding to vagal maneuvers
Shortness of breath at rest or severe
Inability to speak full sentences
New ankle swelling or difficulty lying flat
Signs of heart failure
Follow-up plan
Cardiology appointment within 1 to 2 weeks
Sooner if symptoms are frequent or worsening
Bring medication list to appointment
Discuss ablation with your cardiologist
Ablation cures most cases of focal atrial tachycardia
Success rate over 90%
Activity and driving
No driving until cleared by your doctor if you had fainting or near-fainting
Discuss return to work and exercise with your cardiologist
References
Guidelines and key sources
Primary guidelines
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia
Page RL et al Journal of the American College of Cardiology 2016
Comprehensive SVT management including focal AT ablation recommendations
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar JA et al Journal of the American College of Cardiology 2024
Includes SVT differential and antiarrhythmic principles
AHA 2025 Adult Advanced Life Support Guidelines
Wigginton JG et al Circulation 2025
Cardioversion thresholds and ACLS arrhythmia algorithms
Supporting evidence
Peng G and Zei PC JAMA 2024 Diagnosis and Management of Paroxysmal SVT
Practical review of adenosine vagal maneuvers and rate control agents
Nasir M et al American Family Physician 2023 Common Types of SVT
Ablation success rates and antiarrhythmic selection
Helton MR American Family Physician 2015 Common Types of SVT
Diagnostic approach and initial management
Coding and terminology
ICD-10 I47.1 supraventricular tachycardia including focal AT
SNOMED CT focal atrial tachycardia concept
ICD-10 I47.2 ventricular tachycardia for differential coding
Tisdale JE et al AHA Scientific Statement 2020 Drug-Induced Arrhythmias
Digoxin and theophylline induced AT mechanisms and management
Nielsen JC et al EHRA/HRS/APHRS/LAHRS Expert Consensus 2020 Risk Assessment in Cardiac Arrhythmias
Occupational risk stratification and syncope evaluation
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.